News

FDA approves once-daily Jakafi XR for some myelofibrosis patients

The U.S. Food and Drug Administration (FDA) has approved a new once-daily formulation of Jakafi (ruxolitinib), known as Jakafi XR, for adults with intermediate- or high-risk myelofibrosis. Like the original version of Jakafi, which is taken twice daily, Jakafi XR is also FDA-approved to treat certain people…

Low blood cell counts before treatment may signal higher risk in myelofibrosis

People with myelofibrosis who had low blood cell counts before starting ruxolitinib had shorter overall survival after treatment, according to a new study. “Cytopenias [low blood cell counts] before the start of ruxolitinib treatment have an unfavorable effect on the outcome and survival of patients with myelofibrosis,” researchers wrote in…

Drug combo outperforms standard myelofibrosis treatment in trial

Combining the blood cancer therapy selinexor with Jakafi (ruxolitinib), an oral treatment approved for adults with myelofibrosis, outperformed Jakafi alone in rapidly reducing spleen size and showed promising signs of extending survival. These are the early findings from Karyopharm Therapeutics‘ ongoing global Phase 3 trial, dubbed SENTRY (NCT04562389),…